Finance
Pharmaceutical company announces 2004 financial results
Published in Obesity and Diabetes Week, March 28th, 2005
Nastech ended 2004 with $74.5 million in cash, cash equivalents and short-term investments compared to $25.1 million at December 31, 2003. In December 2004 Nastech completed the sale of 4.25 million shares of our common stock at $13.50 per share and received net proceeds after expenses of approximately $53.0 million. The company also received a $5.0 million license fee from our alliance with Merck during the quarter.
The net loss for the quarter ended December 31, 2004, was $5.9 million or $0.41 per share, compared to a net loss of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Risk Factors
Predictors of type 2 diabetes outlined - Insulin Resistance
Acid-base balance influence risk for insulin resistance syndrome - Obesity and Diabetes
Associations among diabetes, obesity, and the brain reviewed - Obesity and Diabetes
Insulin delivery to muscles delayed after oral glucose load in obese subjects - Obesity and Diabetes
Subsarcolemmal mitochondria deficiency found in obesity and type 2 diabetes - Adipose Tissue
Conjugated linoleic acids stimulate adipose tissue lipogenesis - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
